Duloxetine Dosing for Depression in Patients with Gastroparesis

Initial Dosing Strategy

The American College of Clinical Pharmacology recommends a gradual titration of duloxetine, starting with 30 mg once daily for 1 week, then increasing to 60 mg once daily, to reduce treatment-emergent nausea in patients with gastroparesis 1, 2

The American Psychiatric Association suggests that the target dose for depression is 60 mg once daily, as doses up to 120 mg daily have been studied but show no additional benefits for depression, and higher doses are associated with increased adverse events 2

The American Gastroenterological Association recognizes duloxetine at 60-120 mg/day as an effective treatment for visceral pain in gastroparesis patients, offering dual benefits in this population by treating both depression and visceral pain through serotonin and norepinephrine reuptake inhibition 3, 4

The Mayo Clinic recommends that nausea, the most common adverse effect, is typically mild, transient, and occurs predominantly in the first week of treatment, with approximately 23-29% of patients experiencing it 2

The American College of Clinical Pharmacology recommends assessing for adverse effects at each follow-up visit, particularly nausea, dry mouth, constipation, and dizziness, and monitoring blood pressure as duloxetine can cause modest hypertension 1
The National Institute of Mental Health suggests evaluating therapeutic response using standardized depression scales, and watching for mood changes, particularly during the first few months of treatment 1

The American Academy of Family Physicians recommends tapering duloxetine gradually over at least 2-4 weeks to minimize withdrawal symptoms, including dizziness, headache, nausea, paresthesia, and irritability 1